Imbria Pharmaceuticals

Please note: The information displayed on this page might be outdated.
Imbria Pharmaceuticals: Imbria Pharmaceuticals is a clinical stage company developing novel cardiometabolic therapies designed to substantially improve the lives of patients with life-altering diseases. Their clinical stage pipeline is focused on restoring or improving the cell’s ability to produce energy in disorders where energetic impairment is a fundamental contributor, including cardiovascular disease and specific inborn errors in metabolism. Ninerafaxstat, their lead program, is currently in Phase 2 clinical development in three indications: Hypertrophic cardiomyopathy, stable angina, and heart failure with preserved ejection fraction. The pipeline also includes IMB-203, designed to address the energy deficiency in patients with rare inborn errors of mitochondrial metabolism.
Sector/Industry:
Healthcare
Characteristics:
Based in...
US - New England
Clinical Stage
Phase l or ll, Pre-Clinical Stage
Industry
Biotechnology
Listing
Private
Website:
Profiles:
Address:
265 Franklin Street
Suite 1702
Boston, MA 02116
United States

Company Participants at Fall Private Company Showcase 2022

  • Anne Prener, M.D., Ph.D., President and Chief Executive Officer

Upcoming Company Event Participation